Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 4/20 | 0.53 |
| ▸ | SLC16A1 | P53985 | 3/20 | 0.49 |
| ▸ | MCTS1 | Q9ULC4 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883026 | 0.89 | SLC16A3 (0.55) | SLC16A3SLC16A1MCTS1PPARG | |
| Clobuzarit SCHEMBL187456 | 0.87 | SLC16A3 (0.62) | SLC16A3SLC16A1MCTS1PPARG | |
| SCHEMBL3125403 | 0.86 | IDO1 (0.47) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL11654721 | 0.81 | ABCC4 (0.42) | ABCC4LMNAGAATSHRPTGS1 | |
| SCHEMBL2352150 | 0.81 | RXRA (0.46) | SLC16A3SLC16A1MCTS1PPARGIDO1 | |
| SCHEMBL8935661 | 0.81 | SLC16A3 (0.46) | SLC16A3SLC16A1MCTS1PPARGIDO1 | |
| SCHEMBL2215266 | 0.81 | RXRA (0.46) | SLC16A3SLC16A1MCTS1PPARGLMNA | |
| SCHEMBL2220152 | 0.80 | MAPT (0.45) | — | |
| SCHEMBL10819593 | 0.80 | IDO1 (0.55) | IDO1AGXT | |
| SCHEMBL31377393 | 0.79 | NPC1 (0.53) | SLC16A3SLC16A1MCTS1PPARGHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | HCAR1, HDAC1, H1-0 | SLC16A3 132/4885SLC16A1 44/4885MCTS1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.